Bristol-Myers Squibb to Take Part in the Cowen and Company 39th Annual Health Care Conference

On March 5, 2019 Bristol-Myers Squibb Company (NYSE:BMY) reported that it will take part in a fireside chat at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, in Boston (Press release, Bristol-Myers Squibb, MAR 5, 2019, https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-take-part-cowen-and-company-39th-annual-h [SID1234533949]). Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 11:20 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe

On March 4, 2019 Oncoceutics, Inc. reported that the European Patent Office (EPO) has issued EP 3,068,401 entitled "7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use" with an expiration date of September 12, 2034 (Press release, Oncoceutics, MAR 4, 2019, View Source [SID1234558360]). This patent covers the composition of matter for ONC206, its di-salt formulation, and its use in the treatment of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ONC206, a member of the imipridone family of anti-cancer small molecules, has demonstrated anti-cancer activity and safety in preclinical models and is planned to enter the clinic in 2019. These patents pave the path for the next generation of imipridones to enter the clinic and eventually the market.

This patent is the second issued on ONC206, following the composition of matter patent issued by the US Patent Office on June 28th, 2016, and greatly expands the company’s global IP protection.

"We are pleased that the European Patent Office has recognized ONC206 as an exciting novel invention and granted the appropriate patent protections," said Martin Stogniew, Ph.D., Chief Development Officer of Oncoceutics. "The company’s current patent portfolio provides Oncoceutics with the opportunity to continue imipridone development and eventually provide ONC206 to European patients."

Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019

On March 4, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported a late-breaking poster presentation for its AUTO1 program at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019 to be held March 29 to April 3 in Atlanta, Georgia (Press release, Autolus, MAR 4, 2019, View Source [SID1234550831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation details are as follows. The full text of the abstract will be posted to the AACR (Free AACR Whitepaper) website on March 29.

Abstract Number: CT105
Session Name: PO.CT04 – Phase I-III Trials in Progress: Part 1
TITLE: AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL
Session Date: Monday, April 1, 2019
Session Time: 1:00 PM – 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 17

About AUTO1
AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in safety – while maintaining similar levels of efficacy – compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, AUTO1 may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the T cells’ abilities to engage in serial killing of target cancer cells. In 2018, Autolus signed a license agreement under which Autolus acquired global rights from UCL Business plc (UCLB), the technology-transfer company of UCL, to develop and commercialize AUTO1 for the treatment of B cell malignancies. AUTO1 is currently being evaluated in two Phase 1 studies, one in paediatric ALL and one in adult ALL.
For information about the trials, visit View Source and View Source

Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference

On March 4, 2019 Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that Dr. Christian Itin, chairman and chief executive officer, will present at the Cowen and Company 39th Annual Healthcare Conference in Boston, on March 11, at 2:10 pm ET (Press release, Autolus, MAR 4, 2019, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-present-cowen-and-company-39th-annual [SID1234550822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the investor relations section of the company’s website: View Source An archived replay will be available on the company’s website for a period of 90 days after the conference.

Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

On March 4, 2019 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 11:20 AM ET in Boston, MA (Press release, Jounce Therapeutics, MAR 4, 2019, https://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-present-cowen-and-company-39th-annual-health [SID1234535388]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting "Events & Presentations" in the Investors and Media section of the company’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation